Literature DB >> 23726836

Tetramethylpyrazine attenuates TNF-α-induced iNOS expression in human endothelial cells: Involvement of Syk-mediated activation of PI3K-IKK-IκB signaling pathways.

Zhen Zheng1, Zhiliang Li, Song Chen, Jieyi Pan, Xiaochun Ma.   

Abstract

Endothelial cells produce nitric oxide (NO) by activation of constitutive nitric oxide synthase (NOS) and transcription of inducible NO synthase (iNOS). We explored the effect of tetramethylpyrazine (TMP), a compound derived from chuanxiong, on tumor necrosis factor (TNF)-α-induced iNOS in human umbilical vein endothelial cells (HUVECs) and explored the signal pathways involved by using RT-PCR and Western blot. TMP suppressed TNF-α-induced expression of iNOS by inhibiting IκB kinase (IKK) phosphorylation, IκB degradation and nuclear factor κB (NF-κB) nuclear translocation, which were required for NO gene transcription. Exposure to wortmannin abrogated IKK/IκB/NF-κB-mediated iNOS expression, suggesting activation of such a signal pathway might be phosphoinositide-3-kinase (PI3K) dependent. Spleen tyrosine kinase (Syk) inhibitor piceatannol significantly inhibited NO production. Furthermore, piceatannol obviously suppressed TNF-α-induced IκB phosphorylation and the downstream NF-κB activation, suggesting that Syk is an upstream key regulator in the activation of PI3K/IKK/IκB-mediated signaling. TMP significantly inhibited TNF-α-induced phosphorylation of Syk and PI3K. Our data indicate that TMP might repress iNOS expression, at least in part, through its inhibitory effect of Syk-mediated PI3K phosphorylation in TNF-α-stimulated HUVECs.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endothelial cells; Inducible NO synthase; Phosphoinositide-3-kinase; Spleen tyrosine kinase; Tetramethylpyrazine

Mesh:

Substances:

Year:  2013        PMID: 23726836     DOI: 10.1016/j.yexcr.2013.05.018

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

1.  Thalidomide ameliorates portal hypertension via nitric oxide synthase independent reduced systolic blood pressure.

Authors:  Nicholas G Theodorakis; Yining N Wang; Vyacheslav A Korshunov; Mary A Maluccio; Nicholas J Skill
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

2.  A key mediator, PTX3, of IKK/IκB/NF-κB exacerbates human umbilical vein endothelial cell injury and dysfunction.

Authors:  Yongbo Zhao; Guangxing Feng; Yanzhi Wang; Yuehong Yue; Weichao Zhao
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 3.  Unlocking the Untapped Potential of Endothelial Kinase and Phosphatase Involvement in Sepsis for Drug Treatment Design.

Authors:  Matthijs Luxen; Matijs van Meurs; Grietje Molema
Journal:  Front Immunol       Date:  2022-05-13       Impact factor: 8.786

4.  The role of Syk signaling in antifungal innate immunity of human corneal epithelial cells.

Authors:  Ying Liu; Guiqiu Zhao; Jing Lin; Cui Li; Qing Li; Chengye Che; Qian Wang; Liting Hu
Journal:  BMC Ophthalmol       Date:  2015-06-03       Impact factor: 2.209

5.  Tetramethylpyrazine Protects Retinal Capillary Endothelial Cells (TR-iBRB2) against IL-1β-Induced Nitrative/Oxidative Stress.

Authors:  Xue Zhu; Ke Wang; Kai Zhang; Xuhua Tan; Zhifeng Wu; Song Sun; Fanfan Zhou; Ling Zhu
Journal:  Int J Mol Sci       Date:  2015-09-09       Impact factor: 5.923

Review 6.  Ligustrazine monomer against cerebral ischemia/reperfusion injury.

Authors:  Hai-Jun Gao; Peng-Fei Liu; Pei-Wen Li; Zhuo-Yan Huang; Feng-Bo Yu; Ting Lei; Yong Chen; Ye Cheng; Qing-Chun Mu; Hai-Yan Huang
Journal:  Neural Regen Res       Date:  2015-05       Impact factor: 5.135

Review 7.  Regulatory mechanisms of tetramethylpyrazine on central nervous system diseases: A review.

Authors:  Yue Liu; Guang Yang; Wenqiang Cui; Yunling Zhang; Xiao Liang
Journal:  Front Pharmacol       Date:  2022-09-05       Impact factor: 5.988

8.  Chuanxiong Formulae for Migraine: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials.

Authors:  Chun-Shuo Shan; Qing-Qing Xu; Yi-Hua Shi; Yong Wang; Zhang-Xin He; Guo-Qing Zheng
Journal:  Front Pharmacol       Date:  2018-06-27       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.